Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.

Cancer research - 1 Nov 2016

Allegrezza Michael J, Rutkowski Melanie R, Stephen Tom L, Svoronos Nikolaos, Perales-Puchalt Alfredo, Nguyen Jenny M, Payne Kyle K, Singhal Sunil, Eruslanov Evgeniy B, Tchou Julia, Conejo-Garcia Jose R

Abstract excerpt

Targeted therapies elicit seemingly paradoxical and poorly understood effects on tumor immunity. Here, we show that the MEK inhibitor trametinib abrogates cytokine-driven expansion of monocytic myeloid-derived suppressor cells (mMDSC) from human or mouse myeloid progenitors. MEK inhibition also reduced the production of the mMDSC chemotactic factor osteopontin by tumor cells. Together, these effects reduced mMDSC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to MAP Kinase Signaling System
Share to Myeloid Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelopoiesis

Share to Osteopontin

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridones

Share to Pyrimidinones

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 27803104
DOI: 10.1158/0008-5472.CAN-16-1308
PMCID: PMC5094194

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.PMID 27803104Read ↗

Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapySemantic proximity Read ↗

Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.Semantic proximity Read ↗

Molecular Pathways: Myeloid Complicity in CancerSemantic proximity Read ↗

Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy.Semantic proximity Read ↗

Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growthSemantic proximity Read ↗

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.Semantic proximity Read ↗

Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications.Semantic proximity Read ↗

Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.Semantic proximity Read ↗

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.Semantic proximity Read ↗

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells.Semantic proximity Read ↗

Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.Semantic proximity Read ↗

TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.